Park Youngrok, Lelo Alana, Harris Brent, Berry Deborah L, Chaldekas Krysta, Kim Jung-Sik, Waldman Todd
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.
Methods Mol Biol. 2023;2684:145-151. doi: 10.1007/978-1-0716-3291-8_8.
Bladder cancer is the fifth most common cancer in the United States. Most bladder cancers are early-stage lesions confined to the mucosa or submucosa and are therefore classified as non-muscle-invasive bladder cancer (NMIBC). A minority of tumors are diagnosed after they have invaded the underlying detrusor muscle and are classified as muscle-invasive bladder cancer (MIBC). Mutational inactivation of the STAG2 tumor suppressor gene is common in bladder cancer, and we and others have recently demonstrated that STAG2 mutation status can be used as an independent prognostic biomarker to predict whether NMIBC will recur and/or progress to MIBC. Here we describe an immunohistochemistry-based assay for identifying the STAG2 mutational status of bladder tumors.
膀胱癌是美国第五大常见癌症。大多数膀胱癌是局限于黏膜或黏膜下层的早期病变，因此被归类为非肌层浸润性膀胱癌（NMIBC）。少数肿瘤在侵犯至其下方的逼尿肌后才被诊断出来，被归类为肌层浸润性膀胱癌（MIBC）。STAG2肿瘤抑制基因的突变失活在膀胱癌中很常见，我们和其他人最近已经证明，STAG2突变状态可以用作独立的预后生物标志物，以预测NMIBC是否会复发和/或进展为MIBC。在此，我们描述一种基于免疫组织化学的检测方法，用于鉴定膀胱肿瘤的STAG2突变状态。
